Trans-ethnic Genomic Informed Risk Assessment for Alzheimer's disease: An International Hundred K+ Cohorts Consortium Study

Patrick M. Sleiman^{1,2,3}, Hui-Qi Qu¹, John J Connolly¹, Frank Mentch¹, Alexandre Pereira^{4,5}, Paulo A Lotufo^{4,5}, Stephen Tollman⁶, Ananyo Choudhury⁷, Michele Ramsay⁷, Norihiro Kato⁸, Kouichi Ozaki⁹, Risa Mitsumori⁹, Jae-Pil Jeon¹⁰, Chang Hyung Hong¹¹, Sang Joon Son¹¹, Hyun Woong Roh¹¹, Dong-gi Lee¹¹, Naaheed Mukadam¹², Isabelle F Foote^{12,13}, Charles R Marshall^{12,13}, Adam Butterworth^{14,15}, Bram P Prins^{14,15}, Joseph T Glessner^{1,2,3}, Hakon Hakonarson^{1,2,3,16,17†}, on behalf of the Davos Alzheimer Collaborative and IHCC consortium

Affiliations:

1. The Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, USA.

2. Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA.

3. Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, USA.

4. Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

5. Centro de Pesquisas Clínicas e Epidemiológicas, Hospital Universitário, Universidade de São Paulo, São Paulo, Brazil.

6. MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

7. Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

8. National Center for Global Health and Medicine, Tokyo, 1628655, Japan.

9. Medical Genome Center, Research Institute, National Center for Geriatrics and Gerontology (NCGG), Obu City, Aichi Prefecture, Japan.

10. Korea Biobank Project, Korea National Institute of Health, Osong, Korea.

11. Department of Psychiatry, Ajou University School of Medicine, Suwon, Korea.

12. Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, UK.

13. Genes & Health, Blizard Institute, Queen Mary University of London, UK.

14. MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

15. NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

16. Division of Pulmonary Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, USA.

17. Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.

[†] Corresponding author and reprint requests should be addressed to: Dr. Hakon Hakonarson
Center for Applied Genomics
3615 Civic Center Blvd
Abramson Building
Philadelphia, PA 19104, United States of America
Telephone: 267-426-0088
Fax: 267-426-0363
Email: hakonarson@chop.edu

Word count: xxx

Number of tables and figures: x Tables and x figures.

Abstract

Background Alzheimer's disease (AD) is a complex multifactorial progressive dementia affecting all human populations. As a collaboration model between the International Hundred K+ Cohorts Consortium (IHCC) and the Davos Alzheimer Collaborative (DAC), our aim was to develop a trans-ethnic genomic informed risk assessment (GIRA) algorithm for AD.

Methods The GIRA model was created to include a polygenic risk score (PRS) calculated from the AD GWAS loci, the *APOE* haplotypes, and non-genetic covariates including age, sex and first 3 principal components of population substructure. The model was first validated using a ancestrally diverse dataset from the eMERGE network, and subsequently validated in a South-Asian population in the UK and 3 East-Asian populations. The distributions of the PRS scores were also explored in populations from 3 African regions. In two validation sites, the PRS was tested for associated with the levels of plasma proteomics markers.

Results We created a trans-ethnic GIRA model for the risk prediction of AD and validated the performance of the GIRA model in different populations. The proteomic study in the participant sites identified proteins related to female infertility and autoimmune thyroiditis and associated with the risk scores of AD, highlighting molecular mechanisms underlying the previously observed correlations between these clinical phenotypes.

Conclusions As the initial effort by the IHCC to leverage existing large scale datasets in a collaborative setting with DAC, we developed a trans-ethnic GIRA for AD with the potential of identifying individuals at high risk of developing AD for future clinical applications. The PRS scores in this model also contribute new research discoveries for the molecular pathogenesis of AD as demonstrated by the proteomic data.

Key words: Alzheimer's disease; data sharing; female infertility; genomic informed risk assessment; polygenic risk score; minority population; thyroid; trans-ethnic

Introduction

Alzheimer's disease (AD) is characterized by irreversible neuronal degeneration with no cure to date¹. AD affects all human populations with the prevalence of 8.4% to 13.8% in people aged 65 years and older according to the Centers for Disease Control and Prevention (CDC, <u>https://www.cdc.gov/media/releases/2018/p0920-alzheimers-burden-double-2060.html</u>). Early diagnosis of AD may enable early intervention to minimize the damage to the central nervous system². With older age and female sex as the known risk factors³, AD has been recognized as a complex multifactorial genetic disease⁴. The apolipoprotein E gene (*APOE*) variants have been established as a major susceptibility locus for AD⁵. APOE is a major apoprotein of the lipoproteins chylomicron and very low density lipoproteins (VLDL), with the function of lipid transportation⁶. Amyloid β (A β) forms the extracellular plaque in AD brains, and is the central mechanism of the AD pathogenesis⁷. The APOE is associated with A β aggregation and clearance by physical interaction and sharing common receptors⁸.

Human APOE has three common genetic isoforms APOE2 (112Cys-158Cys), APOE3 (112Cys-158Arg), and APOE4 (112Arg-158Arg), with different amino acid residues at positions 112 and 158 in the N-terminal domain⁸⁹. The APOE genetic isoforms are determined by two single nucleotide polymorphisms: (1) rs429358 (hg38, chr19:44908684:T:C) causes amino acid substitution of Cys to Arg at residue 112; (2) rs7412 (hg38, chr19:44908822:C:T) causes amino acid substitution of Arg to Cys at residue 158¹⁰. Among the 3 APOE isoforms encoded by 3 haplotypes of rs429358 and rs7412 SNPs, the APOE3 haplotype has the most common frequency in all populations studied to date, including African populations ^{11 12}. Compared to the APOE3 haplotype, APOE2 is protective against AD, and APOE4 is predisposing to AD with an odds ratio (OR) value about 2 to 4 for heterozygous carriers^{11 13 14}. Despite the large genetic effect, however, the APOE locus alone is insufficient to explain the genetic susceptibility to AD. A large number of genetic loci associated with AD, e.g. WASH complex subunit 3 (WASHC3), bridging integrator 1 (BIN1), complement C3b/C4b receptor 1 (Knops blood group) (CR1), and cathepsin B (CTSB), have recently been identified in the genome-wide association studies (GWAS) by Jun et al.¹⁵ and Bellenguez et al.¹⁶ with large sample sizes including participants with different ancestries. Additional genetic information from these AD loci may improve the risk prediction of AD and the identification of patients with high risk of AD.

In this study, we developed a genomic informed risk assessment (GIRA) algorithm for AD with both the *APOE* isoforms and the polygenic risk score (PRS) calculated by the multiple AD loci identified in previous GWAS¹⁵¹⁶, as well as known non-genetic risk factors of AD including age and sex. The PRS aggregated the effects of GWAS loci other than the *APOE* locus into a single score, an approach that has been shown as an effective approach to identify patients with high risk of many complex diseases¹⁷⁻¹⁹. In particular, a PRS with selected loci has been demonstrated for precise prediction of type 1 diabetes (T1D)²⁰. Compared to AD with *APOE* as a major genetic locus plus a number of minor loci, T1D has also the human leukocyte antigen (*HLA*) region as a major genetic locus plus a number of minor loci²⁰. Enabled by risk prediction using GIRA, and with more attention given to the high risk patients, this will consequently enable early diagnosis and early intervention for the disease. Nowadays, the major challenge in GIRA models is potential health disparities due to the lack of genomic information in minority or understudied populations²¹. In many cases, effective GIRA models relying on data from large-sample genomewide association studies (GWAS) are only available for the European population as the majority

of GWASs have been done in people with European $ancestry^{22}$. With the aim to eliminate genomics-related health disparities, we leveraged an international effort supported by the International HundredK+ Cohorts Consortium (IHCC)²³, which has brought together large scale cohorts of diverse populations from around the world, who have genome-wide genotype data.

Methods

Genotyping. The genotyping data was imputed with the TOPMed (Version R2 on GRC38) Reference Panel at the TOPMed imputation server (https://imputation.biodatacatalyst.nhlbi.nih.gov), or the Haplotype Reference Consortium (HRC) panel at the Michigan imputation server (https://imputationserver.sph.umich.edu), or the Sanger Imputation Server (African reference panel), at each participant site. No quality issue was reported for the imputation of any of the SNP markers in the GIRA model from any of participating sites. In case of quality issues for the imputation, to find alternative SNP markers based on the specific population and the genotyping arrays would be done in house upon request.

APOE haplotyping. The *APOE* haplotypes were inferred from the two SNPs rs429358 and rs7412, i.e. APOE2=rs429358/T-rs7412/T; APOE3=rs429358/T-rs7412/C; APOE4=rs429358/C-rs7412/C.

GWAS loci. The GWAS loci were identified by the Stage I studies from Jun et al.¹⁵ and Bellenguez et al.¹⁶ The study by Jun et al. included cases/controls with European ancestry (EA, n=13,100/13,220), African Americans (AA, n=1,472/3,511), Japanese (JPN, n=951/894), and Israeli-Arab (IA, n=51/64)¹⁵. The study by Bellenguez et al. included 2,447 diagnosed cases, 46,828 proxy cases of dementia and 338,440 controls, all with European ancestry¹⁶. Multi-allelic variants, indels and rare SNPs with MAF < 3% were excluded from further analysis. The remaining variants from the combined summary stats were LD pruned using an R² threshold of 0.3 resulting in a final list of 74 variants (Supplementary Table 1).

GIRA model. The GIRA model includes 3 components, i.e. *APOE* haplotype, PRS by genomic markers, and covariates including age, sex and the first 3 principal components of population substructure for genetic ancestry correction. The PRS is calculated by the weighted sum of the effect alleles, while weights are the reported odds ratios.

Validation of PRS models. The PRS markers were first validated for their allele frequencies in 4145 ancestrally diverse dementia patients from the electronic medical records and genomics (eMERGE) consortium Phase I-III dataset. Subsequently, the scoring algorithm, SNPs and weights, as well as detailed instructions were disseminated to participant sites (Table 1). Scores were generated on a total of 25,786 participants across a variety of endpoints and returned to the Children's Hospital of Philadelphia (CHOP) for collation. Each site was requested to follow standardized reporting metrics. As all groups did not have accurate age at onset data, we requested odds ratios rather than hazard ratios for the phenotype outcomes (Table 1). Each validation site was required to return:

1) The odds ratio per standard deviation of the PRS distribution with 95% confidence interval (CI);

2) Estimate of model discrimination [Area under the receiver operating characteristic (ROC)

Curve, AUC] with 95% CI of A) the non-*APOE* PRS alone; B) the PRS and *APOE* status; C) The non-genetic predictors alone; D) the full model.

3) Tail discrimination: We set the cutoff for the high risk group at the 97.5% of the PRS. The ORs and 95% CI (and the P-value for the OR) were calculated by comparing the high risk group vs. everybody else. i.e the participants in the top 2.5% of the PRS vs the bottom 97.5%.

4) The sensitivity / specificity as well as negative (NPV) and positive (PPV) predictive values at the proposed cutoff (split by ancestry if appropriate for each cohort).

The NPV/PPV used prevalence adjusted metrics, i.e. PPV = (Sn * Pr) / [(Sn * Pr) + ((1 - Sp) * (1 - Pr))] and NPV = (Sp * (1 - Pr)) / [(Sp * (1 - Pr)) + ((1 - Sn) * Pr)] where Sn = sensitivity, Sp = specificity, and Pr = population based prevalence reflective of the study population

Proteomics study at two participant sites. The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) enrolled 15,105 civil servants aged 35 to 74 years living in six cities ²⁴, addressing the incidence of non-communicable diseases. From the 15,105 participants, 9,333 DNA samples were analyzed for genetic ancestry using a software tool for maximum likelihood estimation of individual ancestries from multi-locus SNP genotype datasets²⁵. The INTERVAL BioResource recruited 45,263 whole blood donors (22,466 men and 22,797 women) between June 11, 2012, and June 15, 2014²⁶. Donors were aged 18 years or older from 25 NHS Blood and Transplant (NSHBT) blood donation centers distributed across England, UK. In addition to the GIRA validation at these two sites, the PRS scores were tested for association with 3,282 plasma protein targets from the SomaLogic proteomics platform (SomaLogic Inc., Boulder, CO, USA).

Exploration of the PRS model in African populations. Without an African cohort of AD patients, we explored the distribution of the PRS scores in African populations in the Africa Wits-INDEPTH Partnership for genomic studies (AWI-Gen) leveraging its access via the IHCC resources²⁷. African populations from three geographic regions (south - South Africa; east – Kenya; and west - Ghana/Burkina Faso) were assessed.

Results

The genetic markers for the PRS model were polymorphic and informative in 4,145 ancestrally diverse dementia patients from the eMERGE consortium (Supplementary Table 2). Four cohorts from three sites, Korea Biobank, NCGG and East London Genes & Health, reported results of the PRS in dementia cases *vs.* controls (Table 2). Except the UKB white cohort, the best performance of prediction of dementia was by the full GIRA model with combination of the PRS component, the *APOE* haplotypes, and the non-genetic covariates. In the risk prediction, either genomic markers alone or non-genetic factors alone is insufficient, while the combined usage of genetic risk factors and non-genetic factors increased the performance of the prediction model. Most importantly, all four cohorts in Table 2 were non-European. A random effects restricted maximum likelihood (REML) meta-analysis of the four AUCs and their variance was 0.674 (0.643-0.706), indicating the potential of a prediction model in the non-European populations.

Further, to assess the potential application of the PRS in African populations, the PRS model was examined in the continental African AWI-Gen cohort including participants from across the continent (<u>https://www.wits.ac.za/research/sbimb/research/awi-gen/</u>)^{28 29} to determine if the SNP

markers forming the PRS are polymorphic and informative in African populations from different geographic regions. As shown, the score is normally distributed with similar variance across African populations (Supplementary Figure 1), indicating it is suitable for use in populations of African ancestry.

In addition to the validation of the prediction model, two sites, ELSA Brazil and INTERVAL UK reported on results of the score as well as results from plasma proteomic analysis. The proteomics analysis showed correlation with APOE haplotypes, including also with blood APOE levels across two separate peptides (Table 3). Correlation of 99 proteins with the full PRS model were also observed with P < 0.05 (Supplementary Table 3). Using the WebGestalt (WEB-based Gene SeT AnaLysis Toolkit) web tool³⁰, over-representation analysis (ORA) of the correlated genes by the DisGeNET approach³¹, highlighted the genes (CEBPB, FSHB, LEP, LHB, LIF) in the gene set C0021361:Female infertility with false discovery rate (FDR)=0.0066779 (Table 4). ORA by the GLAD4U approach³² highlighted the gene sets PA445859:Thyroiditis, Autoimmune (FDR=0.017306, including CD3G, CGA, CXCL9, FAS, LILRB1); PA444172:Fetal Growth (FDR=0.044508, including IGF1, SELP, Retardation IGFBP3, LEP, *TMEM70*): PA443588:Cachexia (FDR=0.044508, including IGF1, LEP, LIF, SELP). Taken together, these results demonstrate enrichment of several genes that influence AD risk, as well as risks for multiple other conditions, including but not limited to female infertility, thyroiditis and autoimmunity. These results warrant further evaluation for risk optimization.

Discussion

As one of the first IHCC multinational studies, we demonstrate the feasibility of developing a trans-ethnic AD GIRA model that is predictive of disease predisposition across diverse populations, globally. In this regard, the IHCC project served as an important resource to examine GIRA and PRS in under-represented populations in genomic studies. The GIRA model performed better than the PRS model in East Asian populations from Japan and Korea, and in South Asian populations of Pakistani/Bangladeshi origin recruited through UK. While lacking a well phenotyped AD cohort of African origin with genetic data, we demonstrate a normal distribution of the PRS scores in different regions in Africa, suggesting that the current PRS score system is potentially informative in African populations. Further assessment of the PRS model in African AD patients is warranted.

In addition to its clinical potential, this study uncovered associations between the AD PRS scores and other disease-related gene sets, leading to novel insights into the pathogenesis of AD. In this regard, we identified association of the AD PRS and genes related to female infertility. Clinically, it has been observed that parity is inversely associated with risk of AD^{33} . The genes related to female infertility identified in this study help explain the increased risk of AD in women, as well as the molecular mechanisms of the pathogenesis of AD in women and how parity decreases the risk of AD. Among the 5 genes related to female infertility identified (Table 4), the lowest P value was seen between PRS and lower level of follicle stimulating hormone subunit beta (encoded by *FSHB*). The physiological function of follicle-stimulating hormone is to induce egg and sperm production³⁴. Genetic variants of *FSHB* have been shown to cause hypogonadotropic hypogonadism in women and men^{35 36}. With The *FSHB* gene as a potential mediator of the pathogenesis of AD, it may also help to explain the clinical correlation between hypogonadism and AD³⁷. More importantly, *FSHB* may represent a new opportunity to develop hormone

therapy for AD^{38} ³⁹. In addition, previous studies have demonstrated correlations between abnormal levels of thyroid-stimulating hormone (TSH) and the risk of AD^{40} . While further studies are warranted, our study identified 5 genes that may mediate this correlation.

Given that this is the first effort by the IHCC to leverage large existing datasets that reside within the IHCC consortium for a trans-ethnic GIRA on AD, we envision an opportunity to scale this to other cohorts within the consortium and expand the number of traits that can be analyzed. As such, the IHCC presents a rich resource of data for collaborative research with trans-ethnic focus, where there is much unmet need at present as this is an area of research that has been largely neglected. We also need to emphasize that this is a proof-of-principle study for an international effort to develop a trans-ethnic GIRA model for precision medicine, whereas to improve the GIRA model as suggested by the currently limited AUC scores is still warranted through further international efforts. As our research efforts continue, we envision efficient data sharing across academia and industry, where we will focus on improving patient health care services for AD and other diseases as well as biomedical research discoveries, leveraging our established GIRA approach.

Supplementary materials

Supplementary Table 1 SNPs and weights for the PRS model

Supplementary Table 2 Frequencies of the genetic markers for the GIRA model in 4,145 ancestrally diverse dementia patients from the eMERGE consortium

Supplementary Table 3 Correlation of 99 proteins with P<0.05 with the full GIRA model

Supplementary Figure 1 Distribution of the PRS in the continental African AWI-GEN cohort from different geographic regions

Acknowledgements We thank all the participants who contributed to and enabled this study.

Ethical Approval

This study was exempted by the Institutional Review Board (IRB) of the Children's Hospital of Philadelphia, USA. Human participant personal information was not shared with the research group and participants were de-identification. All human participants or their proxies provided written informed consent for their respective studies and all the studies were approved by their local and/or national ethics review boards.

Funding

The study was supported by:

All authors were supported by the International HundredK+ Cohorts Consortium (IHCC), which was created in collaboration with the Global Alliance for Genomics and Health (GA4GH) and the Global Genomics Medicine Collaborative (G2MC) with support from the National Institutes of Health and the Wellcome Trust.

The Davos Alzheimer Collaborative (DAC) provided funding to enable completion of the study.

The study was funded in part by an Institutional Development Fund from the Children's Hospital of Philadelphia to the Center for Applied Genomics, and The Children's Hospital of Philadelphia Endowed Chair in Genomic Research.

ELSA-Brasil is funded by the Brazilian Ministry of Health (Department of Science and Technology) and the Ministry of Science, Technology and Innovation (FINEP, Financiadora de Estudos e Projetos), and CNPq (the National Council for Scientific and Technological Development).

Genes & Health has recently been core-funded by Wellcome (WT102627, WT210561), the Medical Research Council (UK) (M009017), Higher Education Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London substantive site), and research delivery support from the NHS National Institute for Health Research Clinical Research Network (North Thames). Genes & Health is/has recently been funded by Alnylam Pharmaceuticals, Genomics PLC; and a Life Sciences Industry Consortium of Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc.

Korea Biobank and Biobank Innovations for Chronic cerebrovascular disease With ALZheimer's disease Study (BICWALZS) are funded by the Korea Disease Control and Prevention Agency for the Korea Biobank Project (#6673-303).

Participants in the INTERVAL randomized controlled trial were recruited with the active collaboration of NHS Blood and Transplant (www.nhsbt.nhs.uk), which has supported fieldwork and other elements of the trial. DNA extraction and genotyping were co-funded by the National Institute for Health Research (NIHR), the NIHR BioResource (http://bioresource.nihr.ac.uk) and the NIHR Cambridge Biomedical Research Centre (BRC) (no. BRC-1215-20014). The academic coordinating centre for INTERVAL was supported by core funding from the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (no. NIHR BTRU-2014-10024), UK Medical Research Council (MRC) (no. MR/L003120/1), British Heart Foundation (nos SP/09/002, RG/13/13/30194 and RG/18/13/33946) and the NIHR Cambridge BRC (no. BRC-1215-20014). A complete list of the investigators and contributors to the INTERVAL trial is provided in ref.17. The academic coordinating centre thanks blood donor centre staff and blood donors for participating in the INTERVAL trial. This work was supported by Health Data Research UK, which is funded by the UK MRC, Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. The views expressed in this manuscript are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

The AWI-Gen Study was funded by the National Human Genome Research Institute (NHGRI), Office of the Director (OD), Eunice Kennedy Shriver National Institute Of Child Health &

Human Development (NICHD), the National Institute of Environmental Health Sciences (NIEHS), the Office of AIDS research (OAR) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), of the National Institutes of Health (NIH) under award number U54HG006938.

Declaration of Conflicting Interests

All authors declare no conflicts of interest with respect to the research, authorship, and/or publication of this article.

Consent for publication

All authors have provided consent for publication of the manuscript.

Availability of supporting data

Supporting data from this study can be obtained by emailing the corresponding author Dr. Hakon Hakonarson.

Table 1. Sites participating in the validation

Site	Genetic ancestry	Phenotypic outcome	N (case/control)
NationalCenterforGeriatricsandGerontology(NCGG)Biobank	Japanese (East Asian)	AD, MCI	Case:1000 Normal Cognitive:1000
East London Genes and Health cohort	British-Pakistani/British- Bangladeshi (South Asian)	All-cause dementia (from secondary/primary care records); MCI/cognitive decline cases excluded	104 cases; 614 controls
Korean Biobank Project	Korean (East Asian)	Phenotype 1: Cortical amyloid positivity (by Flutemetamol PET imaging) (Control: Cortical amyloid negativity)	191:337 (total 528)
		Phenotype 2: CDR global Score 1 or over (Control: CDR global 0.5 or less)	157:539 (total 696)
Africa Wits-INDEPTH partnership for genomic studies (AWI-Gen)	African (Different ethnolinguistic and geographic groups)	Not assessed for AD	Population cross sectional cohort: n=10,700
The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)	Brazilian (Admixed)		
INTERVAL (UK Blood Donors)	European (White British)	Stroop Test (attention and reaction times), Trail Making Test (executive function), Pairs Test (Episodic Memory), Reasoning Tests (intelligence), >3K proteins on the SomaLogic proteomics platform	~9k Cognitive measure; 1140 proteomics
UKBiobank	European (White British)	ICD9/10 diagnoses of AD/dementia derived from hospital inpatient records or patients with date of Alzheimer's disease/dementia report	2923 cases; 226342 controls

Abbreviations: AD, Alzheimer's disease; CDR, Clinical Dementia Rating; ICD, International Classification of Diseases; MCI, mild cognitive impairment; NA, not applicable.

Cohort	Odds ratio per SD	AUC with PRS only	AUC with genetic predictors (PRS and APOE haplotypes)	AUC with non- genetic covariates only	AUC with the full GIRA model*
Korea pheno1	1.186	0.548	0.677(0.628-	0.627(0.576-	0.751(0.705-
	(0.992-1.418)	(0.497-0.600)	0.726)	0.677)	0.796)
Korea pheno2	1.040(0.871-	0.507(0.456-	0.612(0.560-	0.545(0.493-	0.637(0.586-
_	1.243)	0.559)	0.664)	0.597)	0.689)
East London	1.110(0.940-	0.530(0.470-	0.540(0.480-	0.680(0.610-	0.690(0.620-
	1.330)	0.590)	0.600)	0.750)	0.760)
Japan	1.120	0.545(0.520-	0.607(0.582-	0.616(0.591-	0.625(0.601-
		0.570)	0.632)	0.641)	0.650)
UKB white	1.003(0.990-	0.527(0.516-	0.542(0.532-	0.780(0.773-	0.746(0.738-
	1.007)	0.537)	0.553)	0.787)	0.754)

Table 2. Validation of PRS models (95% CIs)

*The full GIRA model: the model with PRS, APOE and non-genetic covariates.

Proteomics ID	R2	P	ВЕТА	SE
APOE.2937.10.2	6.55E-03	0.0057	16.9	6.11
(isoform E3)				
APOE.5312.49.3	0.00475	0.0194	15.03	6.42
(isoform E2)				

Table 3. Correlation of APOE haplotypes with APOE protein levels

Table 4. Genes in the gene-set C0021361:Female infertility associated with AD PRS

Gene Symbol	PRS_R2	Р	ВЕТА	SE	Gene Name
CEBPB	0.004	0.032	15.645	7.274	CCAAT enhancer binding protein beta
FSHB	0.003	0.018	-13.862	5.871	follicle stimulating hormone subunit beta
LEP	0.004	0.035	-15.106	7.147	leptin
LHB	0.002	0.036	-12.101	5.765	luteinizing hormone beta polypeptide
LIF	0.003	0.049	-13.995	7.109	LIF, interleukin 6 family cytokine

Reference:

- 1. Desai AK, Grossberg GT. Diagnosis and treatment of Alzheimer's disease. *Neurology* 2005;64(12 suppl 3):S34-S39.
- 2. Dartigues J-F. Alzheimer's disease: early diagnosis. La Revue du Praticien 2011;61(7):926-30.
- 3. Riedel BC, Thompson PM, Brinton RD. Age, APOE and sex: triad of risk of Alzheimer's disease. *The Journal of steroid biochemistry and molecular biology* 2016;160:134-47.
- 4. Cacabelos R, Fernández-Novoa L, Lombardi V, et al. Molecular genetics of Alzheimer's disease and aging. *Methods and findings in experimental and clinical pharmacology* 2005;27:1-573.
- 5. Roses AD, Saunders AM. APOE is a major susceptibility gene for Alzheimer's disease. *Current opinion in biotechnology* 1994;5(6):663-67.
- 6. Blum CB. Type III Hyperlipoproteinemia: Still Worth Considering? *Progress in cardiovascular diseases* 2016;59(2):119-24. doi: 10.1016/j.pcad.2016.07.007 [published Online First: 2016/08/03]
- 7. Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. *Neurobiology of disease* 2014;72:3-12.
- Kanekiyo T, Xu H, Bu G. ApoE and Aβ in Alzheimer's disease: accidental encounters or partners? *Neuron* 2014;81(4):740-54. doi: 10.1016/j.neuron.2014.01.045 [published Online First: 2014/02/25]
- 9. Phillips MC. Apolipoprotein E isoforms and lipoprotein metabolism. *IUBMB Life* 2014;66(9):616-23. doi: https://doi.org/10.1002/iub.1314
- Belbin O, Dunn JL, Ling Y, et al. Regulatory region single nucleotide polymorphisms of the apolipoprotein E gene and the rate of cognitive decline in Alzheimer's disease. *Human Molecular Genetics* 2007;16(18):2199-208. doi: 10.1093/hmg/ddm171
- 11. Martens YA, Zhao N, Liu C-C, et al. ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias. *Neuron* 2022
- 12. Stevenson-Hoare J, Heslegrave A, Leonenko G, et al. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease. *Brain* 2022:awac128.
- 13. Emrani S, Arain HA, DeMarshall C, et al. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer's disease: a systematic review. *Alzheimer's Research & Therapy* 2020;12(1):141. doi: 10.1186/s13195-020-00712-4
- 14. Li R-X, Ma Y-H, Tan L, et al. Prospective biomarkers of Alzheimer's disease: A systematic review and metaanalysis. *Ageing Research Reviews* 2022:101699.
- 15. Jun GR, Chung J, Mez J, et al. Transethnic genome-wide scan identifies novel Alzheimer's disease loci. *Alzheimer's & dementia : the journal of the Alzheimer's Association* 2017;13(7):727-38. doi: 10.1016/j.jalz.2016.12.012 [published Online First: 2017/02/12]
- 16. Bellenguez C, Küçükali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nature genetics* 2022;54(4):412-36.
- 17. Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. *Human Molecular Genetics* 2019;28(R2):R133-R42. doi: 10.1093/hmg/ddz187
- 18. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nature genetics* 2018;50(9):1219-24.
- 19. Patel AP, Khera AV. Advances and Applications of Polygenic Scores for Coronary Artery Disease. Annual Review of Medicine 2022;74
- 20. Qu HQ, Qu J, Glessner J, et al. Improved Genetic Risk Scoring Algorithm (GRS2') for Type 1 Diabetes Prediction. *Pediatric Diabetes* 2022
- Martin AR, Kanai M, Kamatani Y, et al. Clinical use of current polygenic risk scores may exacerbate health disparities. *Nature genetics* 2019;51(4):584-91. doi: 10.1038/s41588-019-0379-x [published Online First: 2019/03/29]
- 22. Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. Cell 2019;177(1):26-31.
- 23. Manolio TA, Goodhand P, Ginsburg G. The International Hundred Thousand Plus Cohort Consortium: integrating large-scale cohorts to address global scientific challenges. *The Lancet Digital health* 2020;2(11):e567-e68. doi: 10.1016/s2589-7500(20)30242-9 [published Online First: 2020/10/27]
- 24. Aquino EM, Barreto SM, Bensenor IM, et al. Brazilian longitudinal study of adult health (ELSA-Brasil): objectives and design. *American journal of epidemiology* 2012;175(4):315-24.
- 25. Chor D, Pereira A, Pacheco AG, et al. Context-dependence of race self-classification: Results from a highly mixed and unequal middle-income country. *PLOS ONE* 2019;14(5):e0216653. doi: 10.1371/journal.pone.0216653

- 26. Di Angelantonio E, Thompson SG, Kaptoge S, et al. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 □000 donors. *Lancet (London, England)* 2017;390(10110):2360-71. doi: 10.1016/s0140-6736(17)31928-1 [published Online First: 2017/09/25]
- Ramsay M, Sankoh O. African partnerships through the H3Africa Consortium bring a genomic dimension to longitudinal population studies on the continent. *Int J Epidemiol* 2016;45(2):305-8. doi: 10.1093/ije/dyv187 [published Online First: 2015/12/15]
- Ramsay M, Crowther N, Tambo E, et al. H3Africa AWI-Gen Collaborative Centre: a resource to study the interplay between genomic and environmental risk factors for cardiometabolic diseases in four sub-Saharan African countries. *Global health, epidemiology and genomics* 2016;1:e20. doi: 10.1017/gheg.2016.17 [published Online First: 2017/12/26]
- 29. Ali SA, Soo C, Agongo G, et al. Genomic and environmental risk factors for cardiometabolic diseases in Africa: methods used for Phase 1 of the AWI-Gen population cross-sectional study. *Global health action* 2018;11(sup2):1507133. doi: 10.1080/16549716.2018.1507133 [published Online First: 2018/09/28]
- 30. Wang J, Duncan D, Shi Z, et al. WEB-based gene set analysis toolkit (WebGestalt): update 2013. *Nucleic acids research* 2013;41(W1):W77-W83.
- 31. Piñero J, Bravo À, Queralt-Rosinach N, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. *Nucleic acids research* 2016:gkw943.
- 32. Jourquin J, Duncan D, Shi Z, et al. GLAD4U: deriving and prioritizing gene lists from PubMed literature. *BMC Genomics* 2012;13 Suppl 8:S20. doi: 10.1186/1471-2164-13-S8-S20
- 33. Bae JB, Lipnicki DM, Han JW, et al. Does parity matter in women's risk of dementia? A COSMIC collaboration cohort study. *BMC medicine* 2020;18(1):1-11.
- 34. Orlowski M, Sarao MS. Physiology, follicle stimulating hormone. Follicle Stimulating Horm 2018;6
- 35. Matthews CH, Borgato S, Beck-Peccoz P, et al. Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. *Nat Genet* 1993;5(1):83-6. doi: 10.1038/ng0993-83 [published Online First: 1993/09/01]
- 36. Lindstedt G, Nyström E, Matthews C, et al. Follitropin (FSH) deficiency in an infertile male due to FSHbeta gene mutation. A syndrome of normal puberty and virilization but underdeveloped testicles with azoospermia, low FSH but high lutropin and normal serum testosterone concentrations. *Clinical chemistry and laboratory medicine* 1998;36(8):663-5. doi: 10.1515/cclm.1998.118 [published Online First: 1998/11/07]
- 37. Tan R, Pu S. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. *The Aging Male* 2003;6(1):13-17.
- 38. Shao H, Breitner JC, Whitmer RA, et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. *Neurology* 2012;79(18):1846-52.
- 39. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. Jama 2002;288(17):2170-72.
- 40. Tan ZS, Beiser A, Vasan RS, et al. Thyroid function and the risk of Alzheimer disease: the Framingham Study. *Archives of internal medicine* 2008;168(14):1514-20.